Equities

Mabion SA

Mabion SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)16.14
  • Today's Change0.04 / 0.25%
  • Shares traded8.28k
  • 1 Year change-5.89%
  • Beta--
Data delayed at least 15 minutes, as of Oct 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.

  • Revenue in PLN (TTM)139.86m
  • Net income in PLN37.39m
  • Incorporated2009
  • Employees226.00
  • Location
    Mabion SAgen. Mariana Langiewicza 60KONSTANTYNOW LODZKI 95-050PolandPOL
  • Phone+48 422077890
  • Fax+48 422032703
  • Websitehttps://www.mabion.eu/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Read Gene SA11.63m-1.00m66.97m11.00--35.89--5.76-0.1084-0.10841.160.15830.973151.3218.69---8.40-1.06-8.56-1.3192.6788.41-8.63-2.4223.52-2.460.00--40.1416.00-731.53------
Pure Biologics SA68.00k-23.01m68.31m11.00------1,004.63-7.09-8.270.0211-1.820.0016--0.4691,333.33-53.52-65.91-85.74-109.50-1,457.356.97-33,838.23-487.38---7.36-----85.65-60.22-39.41--1.65--
Sds Optic SA370.00-8.98m78.17m--------211,274.10-1.52-1.520.00006-0.05450.0000365.750.0006---74.69---86.32---371,002.80---2,452,795.00--9.61-47.49-----99.61---85.09------
Genomtec SA2.00k-11.00m90.34m----7.69--45,170.31-0.8971-0.89710.00020.95820.0000962.240.0011---47.25---60.10---115,050.00---549,850.00--2.06-88.390.1442---97.50--24.44------
Nanogroup SA1.02k-7.12m98.50m----12.24--96,570.91-0.3541-0.35410.000050.32530.000077.840.0141---45.22-23.18-51.42-26.06-99,397.06-278.03-692,468.60-1,567.572.75-858.810.00---98.55-55.07-840.84---8.99--
Urteste SA0.00-4.28m132.51m----5.12-----3.15-3.150.0018.340.0011.94-----14.28---14.78----------17.80--0.026---100.00---37.59------
Molecure SA355.10k-25.51m179.47m113.00--2.08--505.41-1.52-1.520.02115.130.0032--0.49073,199.10-22.882.64-23.912.76-542.7997.54-7,184.1012.84----0.0657---18.85237.24-19.67---24.82--
Poltreg SA600.00k-17.42m250.89m23.00--3.16--418.16-3.74-3.740.128717.040.005127.123.2226,373.63-14.82-6.51-16.41-7.35-1,804.83-391.38-2,903.50-449.244.21--0.0913--40.04---588.92--214.26--
Mabion SA139.86m37.39m260.86m226.006.981.795.661.872.312.318.659.010.75384.0217.35618,836.3020.15-7.1925.09-16.7978.3058.1026.73-14.271.64101.630.026---7.50--77.94--40.86--
BIOTON SA186.32m-6.85m286.79m358.00--0.479111.131.54-0.0797-0.07972.176.970.23031.0221.19520,435.80-0.8464-1.99-1.04-2.4733.8045.33-3.67-8.610.20850.32950.0864---22.10-5.5160.10-38.690.3284--
Captor Therapeutics SA18.64m-46.69m331.06m104.00--6.53--17.76-10.29-10.294.0810.870.2391--5.26179,230.80-59.88---83.65--51.97---250.46------0.1114--44.15---96.65------
Scope Fluidics SA98.00k-26.68m444.33m40.00--6.58--4,533.95-9.79-9.790.03624.760.0012.530.07162,450.00-27.0452.74-28.5557.32-2,013.27-420.87-27,227.5530,134.7811.32--0.0301--27.72---105.76--89.99--
Selvita SA329.02m47.40m1.05bn382.0022.073.3110.853.182.582.5817.9317.220.54159.294.44388,455.707.80--9.35--78.69--14.41--1.06-0.15090.4236---3.48--130.55------
Data as of Oct 09 2024. Currency figures normalised to Mabion SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

3.56%Per cent of shares held by top holders
HolderShares% Held
Generali PTE SAas of 29 Dec 2023359.99k2.23%
Investors TFI SAas of 31 Dec 2023197.37k1.22%
SSgA Funds Management, Inc.as of 03 Jul 202416.82k0.10%
IPOPEMA TFI SAas of 30 Jun 20231.67k0.01%
PKO TFI SAas of 31 May 2024222.000.00%
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 31 Dec 20230.000.00%
More ▼
Data from 29 Dec 2023 - 28 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.